Shareholder Suits Target BioLife-Repligen Merger; Supplemental Proxy Disclosures Filed
BLFS has more than doubled off its 52-week low of $17.86.
Summary
BioLife Solutions disclosed two shareholder lawsuits seeking to block its $1.5 billion acquisition by Repligen, filed just weeks before the October 5, 2026 stockholder vote. Supplemental proxy disclosures also reveal Repligen expects to pay executive severance at Closing regardless of termination status.
Key Events · M&A and Partnerships · BLFS
-
Shareholder Lawsuits Filed
Two complaints filed September 10, 2026 in New York Supreme Court (Richard Lawrence v. BioLife Solutions, Inc., et al. and James Walsh v. BioLife Solutions, Inc., et al.) allege the Definitive Proxy Statement misrepresents or omits material information regarding financial projections, financial advisor analyses, and director/officer conflicts of interest. Plaintiffs seek to enjoin the merger or rescind it if consummated.
-
Supplemental Executive Compensation Disclosures
Repligen is negotiating offer letters with Dr. Mathew, Mr. Berard, and Mr. Werner for continued employment post-merger with compensation substantially similar to current arrangements. Repligen expects to pay cash severance to named executive officers at Closing regardless of whether a Qualifying Termination occurs, converting double-trigger payments to single-trigger.
-
Potential Excise Tax Reimbursements
Repligen may make tax reimbursement payments to Mr. Wichterman and Mr. Werner for Section 4999 excise taxes, which are not currently determinable but may be material to those individuals. These would be single-trigger payments paid regardless of Qualifying Termination.
-
Stockholder Vote Scheduled
The special meeting of BioLife stockholders to vote on the Merger Agreement is scheduled for October 5, 2026 at 9:00 a.m. Eastern Time, five days after this filing.
Analysis · BLFS · Industrial Applications And Services
With the October 5, 2026 stockholder vote just five days away, two shareholder lawsuits filed on September 10, 2026 seek to enjoin the Repligen acquisition, alleging the Definitive Proxy Statement omits material information about financial projections, financial advisor analyses, and conflicts of interest. In response, Repligen and BioLife filed supplemental disclosures revealing that Repligen is negotiating continued employment for three named executive officers and expects to pay cash severance at Closing regardless of whether a Qualifying Termination occurs — effectively converting double-trigger payments to single-trigger. The litigation adds uncertainty to deal completion, though the companies deny the allegations and intend to defend vigorously.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.5% of the 1629 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLFS was trading at $39.33 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $17.86 to $39.76. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.